

Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/752,619		
		Filing Date	December 29, 2000		
		First Named Inventor	Jesse Salb		
		Art Unit	1616		
		Examiner Name	Dameron Jones		
Sheet	1	of	4	Attorney Docket Number	04646.P003D

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>3</sup> (if known)			
[Signature]		US- 4,474,747	10 - 02 - 1984	Dimo et al.	
		US- 4,887,604	12 - 19 - 1989	Shefer et al.	
		US- 5,043,152	08 - 27 - 1991	Schaefer et al.	
		US- 5,609,851	03 - 11 - 1997	Bennani et al.	
		US- 5,817,289	10 - 06 - 1998	Klaveness et al.	
		US- 6,071,491	06 - 06 - 2000	Epstein et al.	
		US- 5,650,135	07-22-1997	Contag et al.	
		US- 5,796,862	08-18-1998	Pawlicki et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			

Examiner Signature	[Signature]	Date Considered	7/29/03
-----------------------	-------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	09/752,619
Filing Date	December 29, 2000
First Named Inventor	Jesse Salb
Group Art Unit	1616
Examiner Name	Dameron Jones
Attorney Docket Number	04646.P003D

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
DQ		ANDERSON et al., "What does positron emission tomography offer oncology?". <i>Eur. J. Cancer</i> 36:2028-2035 (2000).	
		BENDER et al., "Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer", <i>Hybridoma</i> 18: 87-91 (1999).	
		BROCK et al., "Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas". <i>Br. J. Cancer</i> 82:608-615 (2000).	
		CONTI et al., "PET and [18F]-FDG in oncology: a clinical update", <i>Nuc. Med. Biol.</i> 23:717-735 (1996).	
		DEHDASHTI et al., "Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy", <i>Eur. J. Nucl. Med.</i> 26: 51-56 (1999).	
		FINDLAY et al., "Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil", <i>J. Clin. Oncol.</i> 14: 700-708 (1996).	
		FISCHMAN, "Positron Emission Tomography in the Clinical Evaluation of Metastatic Cancer", <i>J. Clin. Oncol.</i> 14: 691-696 (1996).	
		FISCHMAN, "The role of positron emission tomography in pharmacokinetic analysis", <i>Drug Metab. Rev.</i> 29: 923-956 (1997).	
		FOWLER et al., "PET and drug research and development". <i>J. Nucl. Med.</i> 40:1154-1163 (1999).	
DQ		GERAN et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems", <i>Cancer Chemother. Rep.</i> 3: 51-61 (1972).	
		GREEN et al., "Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose", <i>J. Nucl. Med.</i> 39: 729-734 (1998).	

Examiner  
Signature


Date  
Considered

5/29/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED  
NOV 19 2002  
TECH CENTER 1600/2900

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/752,619
		Filing Date	December 29, 2000
		First Named Inventor	Jesse Salb
		Group Art Unit	1616
		Examiner Name	Dameron Jones
		Attorney Docket Number	04646.P003D
Sheet	3	of	4


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HENDRIKSE et al., "Visualization of multidrug resistance in vivo". <i>Eur. J. Nucl. Med.</i> 26:283-293 (1999).	
		HIETALA, "Ligand-receptor interactions as studied by PET: implications for drug development", <i>Ann. Med.</i> 31: 438-443 (1999).	
		HOH et al., "PET in oncology: will it replace the other modalities?", <i>Semin. Nuc. Med.</i> 27:94-106 (1997).	
		HOEY & SMITH, in Sovak ed., "Handbook of Experimental Pharmacology: Radiocontrast Agents", 73: 22-125, Springer-Verlag, NEW YORK (1984).	
		JERUSALEM et al., "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", <i>Blood</i> 94: 429-433 (1999).	
		KNUUTI et al. "PET as a cardiovascular and metabolic research tool", <i>Ann. Med.</i> 31: 450-456 (1999).	
		PRICE & JONES "Can Positron Emission Tomography (PET) be Used to Detect Subclinical Response to Cancer Therapy?", <i>Eur J Cancer</i> 31A: 1924-1927 (1995).	
		ROMER et al., "Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose", <i>Blood</i> 91: 4464-4471 (1998).	
		SCHELLING et al., "Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer", <i>J. Clin. Oncol.</i> 18:1689-1695 (2000).	
	SCHULTE et al., "Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET". <i>J Nucl. Med.</i> 40: 1637-1643 (1999)		
	SMITH et al., "Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy". <i>J. Clin. Oncol.</i> 18:1676-1688 (2000).		

Examiner Signature		Date Considered	5/29/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



NOV 15 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADEMARK OFFICE

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/752,619
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Filing Date	December 29, 2000
		First Named Inventor	Jesse Salb
		Group Art Unit	1616
		Examiner Name	Dameron Jones
		Attorney Docket Number	04646.P003D
Sheet	4	of	4



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
b9 ↓ P		SOVAK et al. "Contrast media: a journey almost sentimental". <i>Invest Radiol.</i> 29: Suppl 1:S4-14 (1994).	
		VALLBURG et al. "Drug development, radiolabelled drugs and PET", <i>Ann. Med.</i> 31: 432-437 (1999).	
		WAHL et al., "Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation", <i>J. Clin. Oncol.</i> 11: 2101-2111 (1993).	
		WEBER et al., "Reproducibility of metabolic measurements in malignant tumors using FDG PET", <i>J. Nucl. Med.</i> 11:1771-1777 (1999).	
		YOSHIOKA et al., "Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice", <i>J. Nucl. Med.</i> 38: 714-717 (1997).	
		ZHANG et al., "Bioluminescence for biological sensing in living mammals". <i>Adv. Exp. Med. Biol.</i> 471:775-784 (1999).	
		PCT International Search Report for PCT Appln No. PCT/US01/08485, mailed 10-24-01 (9 pages).	
		PCT International Search Report for PCT Appln No. PCT/US01/08663, mailed 10-24-01 (9 pages).	


Examiner Signature	<i>Dameron Jones</i>	Date Considered	5/29/07
--------------------	----------------------	-----------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for Form 1449A/PTO (Modified) (use as many sheets as necessary)				Attorney Docket No.: 04646.P003D		Application Number: 09/752,619	
<div style="text-align: center;">  </div>				First Named Inventor: Jesse Salb			
				Filing Date: 12/29/2000			
Page <u>1</u> of <u>2</u>							
<b>U.S. PATENT DOCUMENTS</b>							
Exam. Initial*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (If known)				
		4,139,605	B1	Felder et al.	02-13-1979	<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> TECH CENTER 1600/2900  NOV 22 2002 </div>	
		4,160,015	B1	Wiegert	07-03-1979		
		3,702,866	B1	Salvesen et al.	11-14-1972		
		4,341,756	B1	Sovak et al.	07-27-1982		
		4,352,788	B1	Felder et al.	10-05-1982		
		4,348,377	B1	Felder et al.	09-07-1982		
		4,439,613	B1	Sovak et al.	03-27-1984		
		4,766,110	B1	Ryan et al.	08-23-1988		
		4,021,481	B1	Almen et al.	05-03-1977		
		2,840,602	B1	Larsen	06-24-1958		
		5,525,327	B1	Baker et al.	06-11-1996		
		4,406,878	B1	DeBoer	09-27-1983		

FOREIGN PATENT DOCUMENTS								
Exam. Initial*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)				
		WIPO	WO 01/67958	A2	Veritas Pharmaceuticals, Inc.	09-20-2001		





Examiner Signature		Date Considered	5/29/03
-----------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). <sup>4</sup>For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for Form 1449A/PTO (Modified) (use as many sheets as necessary)		Attorney Docket No.: 04646.P003D	Application Number: 09/752,619
Page <u>2</u> of <u>2</u>		First Named Inventor: Jesse Salb	
		Filing Date: 12/29/2000	
<b>OTHER ART - NO PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation <sup>2</sup>
		PCT International Search Report for PCT Int'l Appln No. US01/08612, mailed 16 August 2002 (9 pages).	TECH CENTER NOV 22 2002 1600/2900
		XU, YIMING et al. "Synthesis of Radioiodinated 1-Deoxy-Nojirimycin Derivatives: Novel Glucose Analogs," <u>Nuclear Medicine and Biology</u> , Vol. 26, No. 7, p. 833-839 (1999), Document No. XP-001037809.	
		MAGATA, YASUHIRO et al. "Development of a Novel Radioiodinated Glucose Derivative with Interaction to Hexokinase," <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 31, No. 4, p. 317-328 (1992), Document No. XP-000675967.	
		LUTZ, T. et al. " <sup>123</sup> I-Iodobenzoylglucosamines: Glucose Analogues for Heart Imaging," <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 33, No. 4, p. 327-344 (1993), Document No. XP-008002378.	





RECEIVED

Examiner Signature		Date Considered	5/29/03
-----------------------	---	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for Form 1449A/PTO (Modified) (use as many sheets as necessary)		Attorney Docket No.: 04646.P003D	Application Number: 09/752,619
		First Named Inventor: Jesse Salb	
		Filing Date: 12/29/2000	
Page <u>1</u> of <u>1</u>			
<b>OTHER ART - NO PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation <sup>2</sup>
		BECH, LARS; DIEMER, NILS HENRIK; and GJEDDE, ALBERT. "Metabolic effect of topical application of metrizamide to rat brain cortex." <u>Acta Neurol Scand.</u> , vol. 72, pages 427-431 (June 1985).	
		GJEDDE, ALBERT. "The blood-brain barrier is impermeable to metrizamide." <u>Acta Neurol. Scandinav.</u> vol. 66, pages 392-395 (1982).	
		SIGEL, PETER and PETTE, DIRK. "Intracellular localization of glycogenolytic and glycolytic enzymes in white and red rabbit skeletal muscle; a gel film method for coupled enzyme reactions in histochemistry." <u>The Journal of Histochemistry and Cytochemistry</u> , vol. 17, no. 4, pages 225-236 (September 1968).	

RECEIVED  
 FEB 20 2003  
 TECH CENTER 1600/2900

Examiner Signature		Date Considered	5/29/03
--------------------	---	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.